Connor, Clark & Lunn Investment Management (CC&L)’s Pacira BioSciences PCRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.13M | Buy |
214,690
+43,313
| +25% | +$1.04M | 0.02% | 564 |
|
|
2025
Q1 | $4.26M | Buy |
171,377
+127,240
| +288% | +$3.16M | 0.02% | 537 |
|
|
2024
Q4 | $832K | Sell |
44,137
-36,396
| -45% | -$686K | ﹤0.01% | 997 |
|
|
2024
Q3 | $1.21M | Buy |
+80,533
| New | +$1.21M | 0.01% | 822 |
|
|
2023
Q3 | – | Sell |
-27,691
| Closed | -$1.11M | – | 1494 |
|
|
2023
Q2 | $1.11M | Sell |
27,691
-14,232
| -34% | -$570K | 0.01% | 767 |
|
|
2023
Q1 | $1.71M | Buy |
41,923
+25,930
| +162% | +$1.06M | 0.01% | 586 |
|
|
2022
Q4 | $617K | Buy |
+15,993
| New | +$617K | ﹤0.01% | 819 |
|
|
2022
Q2 | – | Sell |
-6,574
| Closed | -$502K | – | 1164 |
|
|
2022
Q1 | $502K | Sell |
6,574
-1,911
| -23% | -$146K | ﹤0.01% | 785 |
|
|
2021
Q4 | $511K | Buy |
+8,485
| New | +$511K | ﹤0.01% | 795 |
|
|
2014
Q2 | – | Sell |
-5,400
| Closed | -$417K | – | 610 |
|
|
2014
Q1 | $417K | Buy |
+5,400
| New | +$417K | ﹤0.01% | 512 |
|